Clinical heterogeneity of neurodegeneration with brain iron accumulation (Hallervorden-Spatz syndrome) and pantothenate kinase-associated neurodegeneration

Movement Disorders

Volumn 19, Issue 1, 2004, Pages 36-42

  Thomas, Madhavi ^a   Hayflick, Susan J ^b,c,d   Jankovic, Joseph ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Brain iron accumulation; Hallervorden Spatz syndrome; NBIA; Neurodegeneration; Pantothenate kinase associated neurodegeneration; PKAN

Indexed keywords

IRON; PANTOTHENATE KINASE;

ADOLESCENT; ADULT; AGED; CHILD; CHOREOATHETOSIS; CHROMOSOME 20P; CLINICAL ARTICLE; CLINICAL FEATURE; COGNITIVE DEFECT; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DYSARTHRIA; DYSTONIA; FEMALE; GAIT DISORDER; GENE IDENTIFICATION; GENE MUTATION; GENETIC HETEROGENEITY; HALLERVORDEN SPATZ DISEASE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INFANT; INTELLECTUAL IMPAIRMENT; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE ATROPHY; PARKINSONISM; PHENOTYPE; PRIORITY JOURNAL; PYRAMIDAL TRACT; RETINA PIGMENT DEGENERATION; REVIEW;

EID: 2342435003     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10650     Document Type: Review

References (39)

1. Hallervorden J, Spatz H. Eigenartige Erkrankung im extrapyramidalen System mit besonderer Beteiligung des Globus pallidus und der Substantia nigra: Ein Beitrag zu den Beziehungen zwischen diesen beiden Zentren. Z Ges Neurol Psychiat 1922;79:254-302.
2. Dooling EC, Schoene WC, Richardson EP Jr. Hallervorden Spatz Syndrome. Arch Neurol 1974;30:70-83.
3. Swaiman KF. Hallervorden-Spatz Syndrome and brain iron metabolism. Arch Neurol 1991;48:1285-1293.
4. Swaiman KF. Hallervorden-Spatz syndrome. Pediatr Neurol 2001; 25:102-108.
5. Jellinger K, Neumayer E. Unusual late-onset type of Hallervorden-Spatz disease. Clinico-pathological study of a case presenting as parkinsonism. J Neurol 1972;203:105-118.
6. Jellinger K. Neuroaxonal dystrophy: its natural history and related disorders. In: Zimmerman HM, editor. Progress in neuropathology, Vol. 2. NY: Grune and Stratton; 1973. p 129-180.
7. Taylor TD, Litt M, Kramer P, et al. Homozygosity mapping of Hallervorden-Spatz syndrome to chromosome 20p12.3-p13. Nat Genet 1996;14:479-481.
8. Zhou B, Westaway SK, Levinson B, Johnson MA, Gitschier J, Hayflick SJ. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet 2001;28:345-349.
9. Hayflick SJ, Westaway SK, Levinson B, Zhou B, Johnson MA, Ching KH, Gitschier J. Genetic, clinical and Radiographic delineation of Hallervorden-Spatz Syndrome. N Engl J Med 2003;348: 33-40.
10. Kalyanasundaram S, Srinivas HV, Deshpande DH. An adult with Hallervorden-Spatz disease: clinical and pathological study. Clin Neurol Neurosurg 1980;82:245-249.
11. Rozdilsky B, Cumings JN, Huston AF. Hallervorden-Spatz disease. Late infantile and adult types, report of two cases. Acta Neuropathol (Berl) 1968;10:1-16.
12. Hardie RJ, Pullon HW, Harding AE, et al. Neuroacanthocytosis. A clinical, haematological and pathological study of 19 cases. Brain 1991;114:13-49.
13. Racette BA, Perry A, D'Avossa G, Perlmutter JS. Late-onset neurodegeneration with brain iron accumulation type 1: expanding the clinical spectrum. Mov Disord 2001;16:1148-1152.
14. Alberca R, Rafel E, Chinchon I, Vadillo J, Navarro A. Late onset parkinsonian syndrome in Hallervorden-Spatz disease. J Neurol Neurosurg Psychiatry 1987;50:1665-1668.
15. Jankovic J, Kirkpatrick JB, Blomquist KA, Langlais PJ, Bird ED. Late-onset Hallervorden-Spatz disease presenting as familial parkinsonism. Neurology 1985;35:227-234.
16. Grimes DA, Lang AE, Bergeron C. Late adult-onset chorea with typical pathology of Hallervorden-Spatz syndrome. J Neurol Neurosurg Psychiatry 2000;69:392-395.
17. Nardocci N, Rumi V, Combi ML, Angelini L, Mirabile D, Bruzzone MG. Complex tics, stereotypies, and compulsive behavior as clinical presentation of a juvenile progressive dystonia suggestive of Hallervorden-Spatz disease. Mov Disord 1994;9:369-371.
18. Scarano V, Pellecchia MT, Filla A, Barone P. Hallervorden-Spatz syndrome resembling a typical Tourette syndrome. Mov Disord 2002;17:618-620.
19. Vaher U, Napa A, Nurmiste A, Piirsoo A, Sibul H, Talvik T. Four siblings with Hallervorden-Spatz disease. Brain Dev 2001;23:236-239.
20. Casteels I, Spileers W, Swinnen T, Demaerel P, Silberstein J, Casaer P, Missotten L. Optic atrophy as the presenting sign in Hallervorden-Spatz syndrome. Neuropediatrics 1994 25:265-267.
21. Battistella PA, Midena E, Suppiej A, Carollo C. Optic atrophy as the first symptom in Hallervorden-Spatz syndrome. Childs Nerv Syst 1998;14:135-138.
22. Newell FW, Johnson RO 2nd, Huttenlocher PR. Pigmentary degeneration of the retina in the Hallervorden-Spatz syndrome. Am J Ophthalmol 1979;88:467-471.
23. Luckenbach MW, Green WR, Miller NR, Moser HW, Clark AW, Tennekoon G. Ocular clinicopathologic correlation of Hallervorden-Spatz syndrome with acanthocytosis and pigmentary retinopathy. Am J Ophthalmol 1983;95:369-382.
24. Angelini L, Nardocci N, Rumi V, Zorzi C, Strada L, Savoiardo M. Hallervorden-Spatz disease: clinical and MRI study of 11 cases diagnosed in life. J Neurol 1992;239:417-425.
25. Tennison MB, Bouldin TW, Whaley RA. Mineralization of the basal ganglia detected by CT in Hallervorden-Spatz syndrome. Neurology 1988;38:154-155
26. Savoiardo M, Halliday WC, Nardocci N, et al. Hallervorden-Spatz disease: MR and pathologic findings. Am J Neuroradiol 1993;14: 155-162.
27. Sethi KD, Adams RJ, Loring DW, el Gammal T. Hallervorden-Spatz syndrome: clinical and magnetic resonance imaging correlations. Ann Neurol 1988;24:692-694.
28. Feliciani M, Curatolo P. Early clinical and imaging (high-field MRI) diagnosis of Hallervorden-Spatz disease. Neuroradiology 1994;36:247-248.
29. Koeppen AH, Dickson AC. Iron in the Hallervorden-Spatz syndrome. Pediatr Neurol 2001;25:148-155.
30. Muller T, Amoiridis G, Kuhn W, Przuntek H. Iron deposits in the subthalamic nuclei in Hallervorden-Spatz disease. Eur Neurol 1999;42:240-241.
31. Curtis AR, Fey C, Morris CM, Bindoff LA, et al. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat Genet 2001;28:350-354.
32. Wills AJ, Sawle GV, Guilbert PR, Curtis AR. Palatal tremor and cognitive decline in neuroferritinopathy. J Neurol Neurosurg Psychiatry 2002;73:91-92.
33. Muthane UB, Shetty R, Panda K, Yasha TC, Jayakumar PN, Taly AB. Hallervordern Spatz disease and acanthocytes. Neurology 1999;53:32A.
34. Malandrini A, Fabrizi GM, Bartalucci P, Salvadori C, Berti G, Sabo C, Guazzi GC. Clinicopathological study of familial late infantile Hallervorden-Spatz disease: a particular form of neuroacanthocytosis. Childs Nerv Syst 1996;12:155-160.
35. Ching KH, Westaway SK, Gitschier J, Higgins JJ, Hayflick SJ. HARP syndrome is allelic with pantothenate kinase-associated neurodegeneration. Neurology 2002;58:1673-1674.
36. Shevell M, Peiffer J. Julius Hallervorden's wartime activities: implications for science under dictatorship. Pediatr Neurol 2001; 25:162-165.
37. Shevell M. Racial hygiene, active euthanasia, and Julius Hallervorden. Neurology 1992;12:2214-2219.
38. Shevell M. Hallervorden and history. N Engl J Med 2003;348:3-4.
39. Hayflick SJ. Hallervorden Spatz Syndrome/Pantothenate Kinase-associated neurodegeneration. In: Pulst S, editors. Genetics of movement disorders. San Diego CA: Academic Press; 2002.